Orexigen Therapeutics (OREX) Reports In-Line Q1 Loss of 14c/Share

Orexigen Therapeutics (NASDAQ: OREX) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $4.36 million versus the consensus estimate of $7.28 million.

As of March 31, 2015, Orexigen had $75.1 million in cash and cash equivalents and an additional $113.5 million in marketable securities, for a total of $188.6 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation